期刊文献+

辛伐他汀对脂多糖诱导新生大鼠心肌成纤维细胞NO生成和AT2R蛋白表达抑制的影响

Effects of Simvastatin on LPS induced NO production and AT2R expression in rat cardiac fibroblasts
下载PDF
导出
摘要 目的研究辛伐他汀(Sim)对脂多糖(LPS)调控心肌成纤维细胞(CFs)一氧化氮(NO)生成和血管紧张素Ⅱ受体2型(AT2R)蛋白表达的干预效应。方法体外培养新生大鼠CFs,以第1代CFs作为实验对象,采用硝酸还原酶法测定细胞内NO产量,Western blot检测细胞AT2R蛋白的表达,以AT2R/β-actin值对AT2R表达进行半定量。结果与LPS(10mg/L)单独作用组相比,0.01μmol/L和0.1μmol/L Sim与LPS共同作用组CFs的NO生成和AT2R/β-actin值无显著差异;在1μmol/L和10μmol/LSim与LPS共同作用组,NO生成量显著低于LPS单独作用组(均P<0.01),而AT2R/β-actin值显著高于LPS单独作用组(分别有P<0.05和P<0.01)。结论高浓度Sim可拮抗LPS引起的NO生成增加和AT2R蛋白表达下降。 AIM To investigate the effects of Simvastatin (Sim) on lipopolysaccharides (LPS)-induced changes in nitric oxide ac fibroblasts (CFs). study. After incubating (NO) production and angiotensin Ⅱ type 2 receptor (AT2R) expression in cardi- METHODS First cultures of neonatal rat CFs were employed in the present cells with LPS, the production of intrinsic nitric oxide (NO) was determined using nitrate reductase measurement. The protein levels of AT2R was determined by Western blot analysis. RESULTS No significant difference was observed in NO production and AT2R protein expression (shown as AT2R/β-actin) when CFs were incubated with Sim (0.01 μmolZL) plus LPS (10 mg/L) or Sim (0.1 μmol/L) plus LPS ( 10 mg/L) and incubated with LPS alone. NO production increased significantly when CFs were incubated with 1 μmol/L or 10 μmol/L Sim in the presence of LPS, compared with LPS alone (both P 〈0.01 ), while AT2R/β-actin decreased significantly in the coincubated groups (P 〈0.05 and P 〈 0.01, respectively). CONCLUSION High concentrations of Sim antagonize LPS in the induction of NO release and the inhibition of AT2R protein expression.
出处 《心脏杂志》 CAS 2007年第3期252-254,共3页 Chinese Heart Journal
基金 陕西省自然科学基金项目资助(No2004C221)
关键词 他汀类药物 心肌成纤维细胞 一氧化氮 血管紧张素Ⅱ受体2型 statins cardiac fibroblasts nitric oxide angiotensin Ⅱ type 2 receptor apoptosis
  • 相关文献

参考文献10

  • 1田建伟,赵连友,王士雯,张海涛,郑强荪,杨学东,徐琳,范延红.阿伐他汀对幼年大鼠心肌成纤维细胞增殖和胶原合成的影响及其意义[J].中华医学杂志,2003,83(2):118-122. 被引量:26
  • 2Son BK,Kozaki K,Iijima K,et al.Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway[J].Circ Res,2006,98(8):1024-1031.
  • 3Massion PB,Pelat M,Belge C,et al.Regulation of the mammalian heart function by nitric oxide[J].Comp Biochem Physiol A Mol Integr Physiol,2005,142(2):144-150.
  • 4Diez J,Lopez B,Gonzalez A,et al.Clinical aspects of hypertensive myocardial fibrosis[J].Curr Opin Cardiol,2001,16(6):328-335.
  • 5Choi BM,Pae HO,Jang SI,et al.Nitric oxide as a pro-apoptotic as well as anti-apototic modulator[J].J Biochem Mol Biol,2002,35(1):116-126.
  • 6de Gasparo M,Catt KJ,Inagami T,et al.International union of pharmacology:XXⅢ.The angiotensin Ⅱ receptors[J].Pharmacol Rev,2000,52(3):415-472.
  • 7Wharton J,Morgan K,Rutherford RA,et al.Differential distribution of angiotensin AT2 receptors in the normal and failing human heart[J].J Pharmacol Exp Ther,1998,284(1):323-336.
  • 8Bartunek J,Weinberg EO,Tajima M,et al.Angiotensin Ⅱ type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin Ⅱ in hypertrophied hearts[J].Circulation,1999,99(1):22-25.
  • 9Yan X,Price RL,Nakayama M,et al.Ventricular-specific expression of angiotensin Ⅱ Type 2 receptor causes dilated cardiomyopathy and heart failure in transgenic mice[J].Am J Physiol Heart Circ Physiol,2003,285(5):H2179-H2187.
  • 10Tamura M,Chen YJ,Howard EF,et al.Lipopolysaccharides and cytokines downregulate the angiotensin Ⅱ type 2 receptor in rat cardiac fibroblasts[J].Eur J Pharmacol,1999,386(2-3):289-295.

二级参考文献9

  • 1Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Circulation, 1991, 83:1849-1865.
  • 2Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA, 1998, 279:1643-1650.
  • 3Simpson P, Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Circ Res, 1982, 50:101-116.
  • 4Pederson TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol, 2000, 86:257-262.
  • 5The LIPID study group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet, 2002, 359:1379-1387.
  • 6Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res, 2001, 49:281-287.
  • 7White CM. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol, 1999, 39:111-118.
  • 8Su SF, Hsiao CL, Chu CW, et al. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol, 2000, 86:514-518.
  • 9Bauersachs J, Galuppo P, Fraccarollo D, et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation, 2001, 104:982-985.

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部